Today, we got the first early look at what ALKS 4230, an engineered interleukin-2 (IL-2) variant immunotherapy, can do at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.
The data cover a series of targets as well as its use as a monotherapy and in combination with Merck’s blockbuster cancer drug Keytruda.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,